Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–998 of 998 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Comparison control condition Clear all

Conditions: Rheumatoid Arthritis (RA)
Interventions: Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 44
States / cities: Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more

Conditions: Cervical Cancer, Papillomavirus Infection, Uterine Diseases, Uterine Cervical Disease
Interventions: COPAN 552c.80 FLOQSwab; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 3,367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Pain
Interventions: Cold pressor test; Other
Lead sponsor: Georgetown University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Fecal Incontinence
Interventions: Iltamiocel, Placebo; Biological · Other
Lead sponsor: Cook MyoSite; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 25
States / cities: La Jolla, California • Orange, California • San Francisco, California + 21 more

Conditions: Attention-deficit/Hyperactivity Disorder
Interventions: Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 79
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 68 more

Conditions: Diabetes Mellitus
Interventions: Alogliptin, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 50
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 47 more

Conditions: Cigarette Smoking Among Patients Currently Receiving Methadone or Buprenorphine Treatment for Opioid Dependence
Interventions: incentive-based contingency management; Behavioral
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Kidney Diseases
Interventions: Not listed
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Depressive Disorder
Interventions: PEER Interactive Report; Device
Lead sponsor: MYnd Analytics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,922 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 2
States / cities: Bethesda, Maryland • Fort Belvoir, Virginia

Conditions: Drinking, Alcohol, Drinking Behavior
Interventions: Control App Version, Standard App Version, Experimental, Feedback App Version; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 25 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Diabetes Mellitus, Depression
Interventions: Healthy Outcomes through Patient Empowerment (HOPE), Enhanced Usual Care; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Generalized Anxiety Disorder
Interventions: Not listed
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Dry Eye Disease
Interventions: OK-101, Placebo; Drug
Lead sponsor: Okyo Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 6
States / cities: Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more

Conditions: COVID-19
Interventions: Exercise Prescription; Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Frisco, Texas

Search by objective public record fields.

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

HPV Self-Sampling in Somali Women (Isbaar Project)

The Effects of Water Temperature on the Cold Pressor Test

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes

Incentive-based Smoking Cessation for Methadone Patients

A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients

Study to Evaluate the Safety and Efficacy of PEER Interactive Versus Treatment as Usual in Subjects With a Primary Diagnosis of Depression

Inhibitory Control Smartphone App

Behavioral Activation Therapy for Rural Veterans With Diabetes and Depression

Locating Regions of Interest in Generalized Anxiety Disorder Using Function Magnetic Resonance Imaging (fMRI)

The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease

Exercise in Adults with Post-Acute Sequelae of SARS-CoV-2 (COVID-19) Infection Study